Type I IFN protects against antigen-induced arthritis

European Journal of Immunology

Volumn 41, Issue 6, 2011, Pages 1687-1695

  Ying, Fei ^a   Chalise, Jaya Prakash ^b   Narendra, Sudeep Chenna ^b   Magnusson, Mattias ^b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Arthritis; Tolerance; Type I IFN

Indexed keywords

ALPHA INTERFERON; ANTIGEN; BOVINE SERUM ALBUMIN; DOUBLE STRANDED RNA; INTERFERON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; IMMUNIZATION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIZATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CATTLE; CELL GROWTH PROCESSES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNITY, ACTIVE; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; RNA, VIRAL; SERUM ALBUMIN, BOVINE; T-LYMPHOCYTES;

EID: 79957551873     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040956     Document Type: Article

References (45)

1. Isaacs, A. and Lindenmann, J., Virus interference. I. The interferon. Proc. R. Soc. B 1957. 147: 258-267.
2. Le Bon, A. and Tough, D. F., Links between innate and adaptive immunity via type I interferon. Curr Opin. Immunol. 2002. 14: 432-436.
3. Tovey, M. G., Lallemand, C., Meritet, J. F. and Maury, C., Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006. 24: S2-46-47.
4. Devendra, D. and Eisenbarth, G. S., Interferon alpha -a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin. Immunol. 2004. 111: 225-233.
5. Banchereau, J. and Pascual, V., Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006. 25: 383-392.
6. Selmi, C., Lleo, A., Zuin, M., Podda, M., Rossaro, L. and Gershwin, M. E., Interferon alpha and its contribution to autoimmunity. Curr. Opin. Invest. Drugs 2006. 7: 451-456.
7. Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S. et al., TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008. 451: 725-729.
8. Park, S. H., Lee, S. R., Hyun, B. H., Kim, B. M. and Sung, Y. C., Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 2008. 26: 3978-3983.
9. Lang, K. S., Recher, M., Junt, T., Navarini, A. A., Harris, N. L., Freigang, S., Odermatt, B. et al., Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005. 11: 138-145.
10. Santiago-Raber, M. L., Baccala, R., Haraldsson, K. M., Choubey, D., Stewart, T. A., Kono, D. H. and Theofilopoulos, A. N., Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003. 197: 777-788.
11. Hron, J. D. and Peng, S. L., Type I IFN protects against murine lupus. J. Immunol. 2004. 173: 2134-2142.
12. Bleich, A., Janus, L. M., Smoczek, A., Westendorf, A. M., Strauch, U., Mahler, M., Hedrich, H. J. et al., CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 2009. 136: 278-287.
13. Olofsson, P., Nerstedt, A., Hultqvist, M., Nilsson, E. C., Andersson, S., Bergelin, A. and Holmdahl, R., Arthritis suppression by NADPH activation operates through an interferon-beta pathway. BMC Biol. 2007. 5: 19.
14. Franssila, R. and Hedman, K., Infection and musculoskeletal conditions: viral causes of arthritis. Best Pract. Res. Clin. Rheumatol. 2006. 20: 1139-1157.
15. Bokarewa, M., Tarkowski, A., Lind, M., Dahlberg, L. and Magnusson, M., Arthritogenic dsRNA is present in synovial fluid from rheumatoid arthritis patients with an erosive disease course. Eur. J. Immunol. 2008. 38: 3237-3244.
16. Cooke, T. D. V., Antigen-induced arthritis, polyarthritis and tenosynovitis. In Greenwald, R. A., Diamond, H. S. (Eds.), CRC Handbook of Animal Models for the Rheumatic Diseases. CRC Press Inc, Boca Radon, FL 1988, pp. 53-81.
17. Weber, F., Wagner, V., Rasmussen, S. B., Hartmann, R. and Paludan, S. R., Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 2006. 80: 5059-5064.
18. van den Berg, W. B., Joosten, L. A. and van Lent, P. L., Murine antigen-induced arthritis. Meth. Mol. Med. 2007. 136: 243-253.
19. Magnusson, M., Zare, F. and Tarkowski, A., Requirement of type I interferon signaling for arthritis triggered by double-stranded RNA. Arthritis Rheum. 2006. 54: 148-157.
20. Petrow, P. K., Thoss, K., Henzgen, S., Katenkamp, D. and Brauer, R., Limiting dilution analysis of the frequency of autoreactive lymph node cells isolated from mice with antigen-induced arthritis. J. Autoimmun. 1996. 9: 629-635.
21. Yarilina, A., Dicarlo, E. and Ivashkiv, L. B., Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by Type I IFNs. J. Immunol. 2007. 178: 2204-2211.
22. Corr, M., Boyle, D. L., Ronacher, L., Flores, N. and Firestein, G. S., Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann. Rheum. Dis. 2009. 68: 257-263.
23. Malmgaard, L., Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 2004. 24: 439-454.
24. Van den Broek, M. F., Müller, U., Huang, S., Aguet, M. and Zinkernagel, R. M., Antiviral defence in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 1995. 69: 4792-4796.
25. Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Kimura, T., Kitagawa, M., Yokochi, T. et al., Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. Genes Cells 1996. 1: 995-1005.
26. Treschow, A. P., Teige, I., Nandakumar, K. S., Holmdahl, R. and Issazadeh-Navikas, S., Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum. 2005. 52: 3739-3748.
27. Triantaphyllopoulos, K. A., Williams, R. O., Tailor, H. and Chernajovsky, Y., Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999. 42: 90-99.
28. Shiozawa, S., Shiozawa, K., Kita, M., Kishida, T., Fujita, T. and Imura, S., A preliminary study on the effect of alpha-interferon treatment on the joint inflammation and serum calcium in rheumatoid arthritis. Br. J. Rheumatol. 1992. 31: 405-408.
29. Conigliaro, P., Perricone, C., Benson, R. A., Garside, P., Brewer, J. M., Perricone, R. and Valesini, G., The type I IFN system in rheumatoid arthritis. Autoimmunity. 2010. 43: 220-225.
30. Nadir, F., Fagiuoli, S., Wright, H. I., Nadir, A., Hopp, E., Gavaler, J. and Van Thiel, D. H., Rheumatoid arthritis: a complication of interferon therapy. J. Okla State Med. Assoc. 1994. 87: 228-230.
31. Zare, F., Bokarewa, M., Nenonen, N., Bergstrom, T., Alexopoulou, L., Flavell, R. A. and Tarkowski, A., Arthritogenic properties of double-stranded (viral) RNA. J. Immunol. 2004. 172: 5656-5663.
32. Rontzsch, A., Thoss, K., Petrow, P. K., Henzgen, S. and Brauer, R., Amelioration of murine antigen-induced arthritis by dehydroepiandrosterone (DHEA). Inflamm. Res. 2004. 53: 189-198.
33. McRae, B. L., Nagai, T., Semnani, R. T., van Seventer, J. M. and van Seventer, G. A., Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood 2000. 96: 210-217.
34. Erickson, S., Sangfelt, O., Castro, J., Heyman, M., Einhorn, S. and Grander, D., Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins. Cell Growth Differ. 1999. 10: 575-582.
35. Krishnaswamy, G., Smith, J. K., Srikanth, S., Chi, D. S., Kalbfleisch, J. H. and Huang, S. K., Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J. Interferon Cytokine Res. 1996. 16: 819-827.
36. Baban, B., Hansen, A. M., Chandler, P. R., Manlapat, A., Bingaman, A., Kahler, D. J., Munn, D. H. et al., A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 2005. 17: 909-919.
37. + T cells. Arthritis Res. Ther. 2005. 7: R291-R301 Epub 2005 Jan 2011.
38. van den Berg, W. B. and Miossec, P., IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009. 5: 549-553.
39. + T cells. Clin. Immunol. 2009. 134: 340-344.
40. +T cell response during cross-priming. J. Immunol. 2006. 176: 4682-4689.
41. Giacomini, P., Fisher, P. B., Duigou, G. J., Gambari, R. and Natali, P. G., Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Res. 1988. 8: 1153-1161.
42. Yoshino, S., Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp. Immunol. Microbiol. Infect. Dis. 1996. 19: 133-138.
43. Ho, H. H. and Ivashkiv, L. B., Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 2006. 281: 14111-14118.
44. Lories, R. J., Derese, I., de Bari, C. and Luyten, F. P., Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 2007. 56: 489-497.
45. Sharif, M. N., Sosic, D., Rothlin, C. V., Kelly, E., Lemke, G., Olson, E. N. and Ivashkiv, L. B., Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 2006. 203: 1891-1901.